Developer docs
API playgroundTry for free, no card

Search company profiles

Tern Therapeutics

Full company profile

uuid0000xb9

Namestring
Tern Therapeutics
Legal namestring
Tern Therapeutics, LLC
Websiteurl
terntx.com
Company typeenum
Private
Founded yearint
2023
Descriptiontext

Tern Therapeutics, LLC is a privately-held clinical-stage biotechnology company founded in 2023 and headquartered in Washington, DC, developing one-time adeno-associated virus (AAV9) gene therapies for CLN2 Batten disease, a rare pediatric neurodegenerative disorder caused by TPP1 enzyme deficiency. The company's pipeline consists of two in-licensed assets acquired from REGENXBIO in August 2024: TTX-381, an intravitreal AAV9 gene therapy designed to deliver a working copy of the TPP1 gene directly to the retina for treatment of the ocular manifestations of CLN2 disease (progressive vision loss); and TTX-181, an AAV gene therapy designed to deliver TPP1 to the central nervous system via cerebrospinal fluid administration for treatment of the CNS manifestations (seizures, motor and cognitive decline). Tern has demonstrated clinical proof-of-concept data including 100% photoreceptor preservation in treated eyes of TTX-381 patients through 12 months, a 27- to 55-fold increase in CSF TPP1 levels and 90% seizure frequency reduction with TTX-181, and no serious adverse events related to either product.

The company is pre-revenue and operates a clinical development and eventual commercialization model. TTX-381 is currently in an open-label Phase I/II trial at Great Ormond Street Hospital in London and University Medical Center Hamburg Eppendorf in Germany, with regulatory engagement spanning the FDA (Fast Track, RMAT, Rare Pediatric Disease, Orphan Drug, CDRP selection) and the UK MHRA (Innovation Passport under ILAP). The go-to-market motion centers on clinical trial execution at specialized pediatric centers, supplemented by a global expanded access program for compassionate use, patient advocacy partnerships with BDFA, BDSRA, and BDSRA Australia to support enrollment, and scientific communication through major medical conferences including WORLDSymposium, the International Congress on NCL, and ARVO.

Tern was founded by three former REGENXBIO executives — CEO Alex M. Bailey, PhD, CMO Christina Ohnsman, MD, and CFO/CAO Matthew Rosini — all of whom were integral leaders in the original CLN2 programs at their prior employer. The company raised $15 million in seed financing in August 2024 led by ATW Partners and Steve Oliveira of Nemean Asset Management, and operates with 1-10 employees. Future revenue is expected to derive from one-time gene therapy product sales and/or licensing economics, contingent on regulatory approval in major markets.

Short descriptiontext

Tern Therapeutics is a privately-held, clinical-stage biotechnology company developing one-time AAV9 gene therapies (TTX-381 and TTX-181) to treat ocular and CNS manifestations of CLN2 Batten disease in pediatric patients.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersWashington, United States
HQ citystring
Washington
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
AAV gene therapy, rare disease therapeutics, CLN2 Batten disease, ocular gene therapy, CNS gene therapy
Industry5 codes
PRIMARYHLAAACAE
Gene Therapy for Rare/Monogenic Diseases
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAG
Ophthalmology Gene Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAH
Neurology/CNS Gene Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAA
AAV Vector Gene Therapy Developers
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAIAIAA
Genetic & Genomic Rare Disease Therapeutics
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Gene Therapy Pharmaceuticals
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Gene Therapy Development and Commercialization
TypeOne Time License
Description

Pre-revenue clinical stage biotechnology company developing one-time gene therapies for rare diseases. The company is focused on advancing TTX-381 and TTX-181 through clinical development toward regulatory approval and commercialization.

terntx.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Tern Therapeutics develops one-time AAV-based gene therapies targeting rare genetic diseases, with an initial pipeline focused on CLN2 (a form of Batten disease). Its lead candidate TTX-381 delivers a working copy of the TPP1 gene to the retina to address ocular manifestations (vision loss), and TTX-181 delivers TPP1 to the central nervous system to address neurological degeneration. Both programs are investigational, in clinical development, and were in-licensed from REGENXBIO.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 100% of treated eyes (6/6) showed photoreceptor preservation with stabilization or improvement in ellipsoid zone loss at 12 months
+4 more records
Product overview1 text field

Tern Therapeutics is a privately-held biotechnology company developing transformative one-time AAV gene therapies for rare diseases. The company's initial therapeutic pipeline consists of two gene therapy products: TTX-381, a one-time gene therapy for the ocular manifestations of CLN2 Batten disease (targeting vision loss), and TTX-181, a one-time gene therapy for the CNS manifestations of CLN2 Batten disease (targeting neurological degeneration). Both products deliver a working copy of the TPP1 gene to address enzyme deficiency in patients with CLN2 disease.

Product and service2 records
1TTX-381
CategoryGene Therapy Pharmaceutical
Description

Investigational one-time AAV9 gene therapy that delivers a working copy of the TPP1 gene directly to the retina, intended as a durable source of TPP1 enzyme activity to treat ocular manifestations (vision loss) in patients with CLN2 Batten disease. Currently in Phase I/II clinical testing in the UK and Germany.

2TTX-181
Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2024-08-27
Description

Tern Therapeutics entered into a global licensing agreement with REGENXBIO for RGX-381 and RGX-181 (now designated TTX-381 and TTX-181 respectively) to form its initial therapeutic pipeline. These are novel one-time gene therapy products for treatment of ocular and CNS manifestations of CLN2 disease.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

BDFA is the only patient organization in the UK for families affected by Batten disease. They expressed support for Tern's advancement of CLN2 programs and the ocular trial in the UK.

3Batten Disease Support, Research & Advocacy (BDSRA)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

BDSRA is a major US patient advocacy organization for Batten disease. They expressed strong support for the transition of gene therapy programs to Tern's team, noting the team's familiarity with programs and connection to CLN2 community.

terntx.com
4BDSRA Australia
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Australian affiliate of BDSRA providing support and collaboration for Tern's CLN2 programs in the Australian region.

terntx.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

World-renowned children's hospital in London, UK serving as the primary clinical trial site for TTX-381 Phase I/II study. Dr. Robert Henderson serves as Principal Investigator and Consultant Retinal Surgeon.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Leading European center for CLN2 research with the largest cohort of CLN2 patients worldwide. UKE received CTA approval from Germany's Paul-Ehrlich-Institut and opened as second clinical trial site for TTX-381 in October 2025. Dr. Angela Schulz serves as Principal Investigator.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Brazilian hospital where physician investigators conducted a single-patient, investigator-initiated study of TTX-181 in late 2022. Dr. Carolina Fischinger Moura de Souza and Dr. Roberto Giugliani presented the two-year follow-up data.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Voyager Therapeutics is a clinical-stage gene therapy company developing AAV-based treatments for severe neurological diseases, including rare CNS indications. Comparable in AAV platform, neurological focus, and pipeline-stage maturity.

TypeDirect peer
Description

Abeona Therapeutics is a clinical-stage gene therapy company developing AAV-based treatments for rare diseases including CLN1 (infantile Batten disease) and CLN3 (juvenile Batten disease). Directly comparable as a Batten disease gene therapy peer with similar regulatory pathway and ultra-rare indication focus.

TypeDirect peer
Description

Passage Bio is a clinical-stage AAV gene therapy company focused on rare CNS disorders using AAV9 and AAV1 vectors. Comparable in technology platform (AAV), therapeutic area (rare CNS), and clinical-stage positioning.

TypeBroad incumbent
Description

Spark Therapeutics developed and commercialized Luxturna, the first FDA-approved gene therapy for an inherited disease (RPE65-mediated retinal dystrophy), and was acquired by Roche. Comparable as a pioneer in ocular gene therapy with regulatory and commercial experience directly relevant to TTX-381.

TypeEmerging player
Description

Solid Biosciences is a clinical-stage genetic medicines company developing AAV gene therapies for rare neuromuscular diseases. Comparable in AAV gene therapy modality, clinical stage, and rare disease therapeutic focus.

TypeDirect peer
Description

Taysha is a clinical-stage gene therapy company using AAV9 vectors to develop treatments for rare CNS diseases including CLN1 and CLN7 forms of Batten disease. Comparable in technology platform, vector choice (AAV9), and focus on ultra-rare CNS indications.

TypeBroad incumbent
Description

Ultragenyx is a commercial-stage rare disease company with gene therapy programs and a strong ultra-rare disease commercialization infrastructure. Comparable for the orphan disease regulatory pathway and ultra-rare pricing strategy that Tern's products would follow.

TypeDirect peer
Description

REGENXBIO is the originator of the TTX-381 and TTX-181 programs that Tern licensed, and a leading AAV gene therapy developer with a broad pipeline including CNS and ocular assets. It is the most directly comparable peer given shared technology platform and overlapping therapeutic areas.

TypeBroad incumbent
Description

BioMarin is an established rare disease biotech with a commercial gene therapy (Roctavian for hemophilia A) and multiple rare disease franchises. Comparable as a broader rare-disease-focused biotech with experience commercializing high-cost, ultra-rare therapies and managing payer relationships.

TypeDirect peer
Description

Neurogene is a clinical-stage genetic medicines company developing AAV-based gene therapies for rare neurological diseases, including programs in Batten disease. Comparable in therapeutic focus (rare neurological/ocular disease), modality (AAV gene therapy), and stage (clinical).

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance6 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Tern Therapeutics

Gene Therapy Pharmaceuticalsterntx.com

Tern Therapeutics is a privately-held, clinical-stage biotechnology company developing one-time AAV9 gene therapies (TTX-381 and TTX-181) to treat ocular and CNS manifestations of CLN2 Batten disease in pediatric patients.

What Tern Therapeutics does

Tern Therapeutics, LLC is a privately-held clinical-stage biotechnology company founded in 2023 and headquartered in Washington, DC, developing one-time adeno-associated virus (AAV9) gene therapies for CLN2 Batten disease, a rare pediatric neurodegenerative disorder caused by TPP1 enzyme deficiency. The company's pipeline consists of two in-licensed assets acquired from REGENXBIO in August 2024: TTX-381, an intravitreal AAV9 gene therapy designed to deliver a working copy of the TPP1 gene directly to the retina for treatment of the ocular manifestations of CLN2 disease (progressive vision loss); and TTX-181, an AAV gene therapy designed to deliver TPP1 to the central nervous system via cerebrospinal fluid administration for treatment of the CNS manifestations (seizures, motor and cognitive decline). Tern has demonstrated clinical proof-of-concept data including 100% photoreceptor preservation in treated eyes of TTX-381 patients through 12 months, a 27- to 55-fold increase in CSF TPP1 levels and 90% seizure frequency reduction with TTX-181, and no serious adverse events related to either product.

The company is pre-revenue and operates a clinical development and eventual commercialization model. TTX-381 is currently in an open-label Phase I/II trial at Great Ormond Street Hospital in London and University Medical Center Hamburg Eppendorf in Germany, with regulatory engagement spanning the FDA (Fast Track, RMAT, Rare Pediatric Disease, Orphan Drug, CDRP selection) and the UK MHRA (Innovation Passport under ILAP). The go-to-market motion centers on clinical trial execution at specialized pediatric centers, supplemented by a global expanded access program for compassionate use, patient advocacy partnerships with BDFA, BDSRA, and BDSRA Australia to support enrollment, and scientific communication through major medical conferences including WORLDSymposium, the International Congress on NCL, and ARVO.

Tern was founded by three former REGENXBIO executives — CEO Alex M. Bailey, PhD, CMO Christina Ohnsman, MD, and CFO/CAO Matthew Rosini — all of whom were integral leaders in the original CLN2 programs at their prior employer. The company raised $15 million in seed financing in August 2024 led by ATW Partners and Steve Oliveira of Nemean Asset Management, and operates with 1-10 employees. Future revenue is expected to derive from one-time gene therapy product sales and/or licensing economics, contingent on regulatory approval in major markets.

Tern Therapeutics firmographics

Firmographics
Name
Tern Therapeutics
Legal name
Tern Therapeutics, LLC
Website
https://terntx.com
Company type
Private
Founded year
2023
Operating status
Operating
Headcount range
1–10 employees
Short description
Tern Therapeutics is a privately-held, clinical-stage biotechnology company developing one-time AAV9 gene therapies (TTX-381 and TTX-181) to treat ocular and CNS manifestations of CLN2 Batten disease in pediatric patients.
Ownership category
akta.pro rank

Tern Therapeutics industry classification

Industry
Product category
Gene Therapy Pharmaceuticals
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAACAE
Gene Therapy for Rare/Monogenic Diseases
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAG
Ophthalmology Gene Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAH
Neurology/CNS Gene Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAA
AAV Vector Gene Therapy Developers
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAIAIAA
Genetic & Genomic Rare Disease Therapeutics
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals

Keywords

  • AAV gene therapy
  • Rare disease therapeutics
  • CLN2 Batten disease
  • Ocular gene therapy
  • CNS gene therapy

Where Tern Therapeutics is headquartered

Location

Headquarters

HQ city
Washington
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Tern Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

  1. Gene Therapy Development and Commercialization: Pre-revenue clinical stage biotechnology company developing one-time gene therapies for rare diseases. The company is focused on advancing TTX-381 and TTX-181 through clinical development toward regulatory approval and commercialization.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels4 records

Tern Therapeutics product offering

Product offering

Core offering

Tern Therapeutics develops one-time AAV-based gene therapies targeting rare genetic diseases, with an initial pipeline focused on CLN2 (a form of Batten disease). Its lead candidate TTX-381 delivers a working copy of the TPP1 gene to the retina to address ocular manifestations (vision loss), and TTX-181 delivers TPP1 to the central nervous system to address neurological degeneration. Both programs are investigational, in clinical development, and were in-licensed from REGENXBIO.

Product overview

Tern Therapeutics is a privately-held biotechnology company developing transformative one-time AAV gene therapies for rare diseases. The company's initial therapeutic pipeline consists of two gene therapy products: TTX-381, a one-time gene therapy for the ocular manifestations of CLN2 Batten disease (targeting vision loss), and TTX-181, a one-time gene therapy for the CNS manifestations of CLN2 Batten disease (targeting neurological degeneration). Both products deliver a working copy of the TPP1 gene to address enzyme deficiency in patients with CLN2 disease.

Differentiator

Problem solved

Functional benefit

Products and services

  • TTX-381 Investigational one-time AAV9 gene therapy that delivers a working copy of the TPP1 gene directly to the retina, intended as a durable source of TPP1 enzyme activity to treat ocular manifestations (vision loss) in patients with CLN2 Batten disease. Currently in Phase I/II clinical testing in the UK and Germany.
  • TTX-181

Quantifiable outcome

  • 100% of treated eyes (6/6) showed photoreceptor preservation with stabilization or improvement in ellipsoid zone loss at 12 months
  • +4 more outcomes

Companies that use Tern Therapeutics

Customer profile

Segments1 record

Ideal customer profiles2 records

Tern Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

Tern Therapeutics partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered core and minor.

  • REGENXBIO Inc.coreTechnology or Integration · 27 August 2024Tern Therapeutics entered into a global licensing agreement with REGENXBIO for RGX-381 and RGX-181 (now designated TTX-381 and TTX-181 respectively) to form its initial therapeutic pipeline. These are novel one-time gene therapy products for treatment of ocular and CNS manifestations of CLN2 disease.
  • Batten Disease Family Association (BDFA)coreStrategic or Co-development PartnerBDFA is the only patient organization in the UK for families affected by Batten disease. They expressed support for Tern's advancement of CLN2 programs and the ocular trial in the UK.
  • Batten Disease Support, Research & Advocacy (BDSRA)coreStrategic or Co-development PartnerBDSRA is a major US patient advocacy organization for Batten disease. They expressed strong support for the transition of gene therapy programs to Tern's team, noting the team's familiarity with programs and connection to CLN2 community.
  • BDSRA AustraliaminorStrategic or Co-development PartnerAustralian affiliate of BDSRA providing support and collaboration for Tern's CLN2 programs in the Australian region.
  • Great Ormond Street Hospital (GOSH)coreStrategic or Co-development PartnerWorld-renowned children's hospital in London, UK serving as the primary clinical trial site for TTX-381 Phase I/II study. Dr. Robert Henderson serves as Principal Investigator and Consultant Retinal Surgeon.
  • University Medical Center Hamburg Eppendorf (UKE)coreStrategic or Co-development PartnerLeading European center for CLN2 research with the largest cohort of CLN2 patients worldwide. UKE received CTA approval from Germany's Paul-Ehrlich-Institut and opened as second clinical trial site for TTX-381 in October 2025. Dr. Angela Schulz serves as Principal Investigator.
  • Hospital de Clinicas Porto AlegreminorStrategic or Co-development PartnerBrazilian hospital where physician investigators conducted a single-patient, investigator-initiated study of TTX-181 in late 2022. Dr. Carolina Fischinger Moura de Souza and Dr. Roberto Giugliani presented the two-year follow-up data.

Scale indicators3 records

Recent moves7 records

Expansion highlights5 records

Tern Therapeutics competitors and assessment

Company assessment

Direct peers

  • Voyager Therapeutics: Voyager Therapeutics is a clinical-stage gene therapy company developing AAV-based treatments for severe neurological diseases, including rare CNS indications. Comparable in AAV platform, neurological focus, and pipeline-stage maturity.
  • Abeona Therapeutics: Abeona Therapeutics is a clinical-stage gene therapy company developing AAV-based treatments for rare diseases including CLN1 (infantile Batten disease) and CLN3 (juvenile Batten disease). Directly comparable as a Batten disease gene therapy peer with similar regulatory pathway and ultra-rare indication focus.
  • Passage Bio: Passage Bio is a clinical-stage AAV gene therapy company focused on rare CNS disorders using AAV9 and AAV1 vectors. Comparable in technology platform (AAV), therapeutic area (rare CNS), and clinical-stage positioning.
  • Taysha Gene Therapies: Taysha is a clinical-stage gene therapy company using AAV9 vectors to develop treatments for rare CNS diseases including CLN1 and CLN7 forms of Batten disease. Comparable in technology platform, vector choice (AAV9), and focus on ultra-rare CNS indications.
  • REGENXBIO: REGENXBIO is the originator of the TTX-381 and TTX-181 programs that Tern licensed, and a leading AAV gene therapy developer with a broad pipeline including CNS and ocular assets. It is the most directly comparable peer given shared technology platform and overlapping therapeutic areas.
  • Neurogene: Neurogene is a clinical-stage genetic medicines company developing AAV-based gene therapies for rare neurological diseases, including programs in Batten disease. Comparable in therapeutic focus (rare neurological/ocular disease), modality (AAV gene therapy), and stage (clinical).

Broad incumbents

  • Spark Therapeutics (Roche): Spark Therapeutics developed and commercialized Luxturna, the first FDA-approved gene therapy for an inherited disease (RPE65-mediated retinal dystrophy), and was acquired by Roche. Comparable as a pioneer in ocular gene therapy with regulatory and commercial experience directly relevant to TTX-381.
  • Ultragenyx Pharmaceutical: Ultragenyx is a commercial-stage rare disease company with gene therapy programs and a strong ultra-rare disease commercialization infrastructure. Comparable for the orphan disease regulatory pathway and ultra-rare pricing strategy that Tern's products would follow.
  • BioMarin Pharmaceutical: BioMarin is an established rare disease biotech with a commercial gene therapy (Roctavian for hemophilia A) and multiple rare disease franchises. Comparable as a broader rare-disease-focused biotech with experience commercializing high-cost, ultra-rare therapies and managing payer relationships.

Emerging players

  • Solid Biosciences: Solid Biosciences is a clinical-stage genetic medicines company developing AAV gene therapies for rare neuromuscular diseases. Comparable in AAV gene therapy modality, clinical stage, and rare disease therapeutic focus.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Tern Therapeutics compliance and trust

Trust signal

Compliance6 records

Tern Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Tern Therapeutics leadership team

Management profile

Number of profiles

Profiles3 records

Tern Therapeutics funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Tern Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Tern Therapeutics

What does Tern Therapeutics do?

Tern Therapeutics develops one-time AAV-based gene therapies targeting rare genetic diseases, with an initial pipeline focused on CLN2 (a form of Batten disease). Its lead candidate TTX-381 delivers a working copy of the TPP1 gene to the retina to address ocular manifestations (vision loss), and TTX-181 delivers TPP1 to the central nervous system to address neurological degeneration. Both programs are investigational, in clinical development, and were in-licensed from REGENXBIO.

Is Tern Therapeutics a public or private company?

Tern Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Tern Therapeutics founded?

Tern Therapeutics was founded in 2023. It employs 1 to 10 people.

Where is Tern Therapeutics based?

Tern Therapeutics is headquartered in Washington, United States, in the North America region.

How does Tern Therapeutics make money?

One revenue line is on record: gene Therapy Development and Commercialization.

Who are Tern Therapeutics's main competitors?

Direct peers on record are Voyager Therapeutics, Abeona Therapeutics, Passage Bio, Taysha Gene Therapies, REGENXBIO and Neurogene. Broad incumbents are Spark Therapeutics (Roche), Ultragenyx Pharmaceutical and BioMarin Pharmaceutical. Solid Biosciences is listed as an emerging player.

Does Tern Therapeutics have an API?

No public API is recorded for Tern Therapeutics.

What industry is Tern Therapeutics in?

Tern Therapeutics's product category is Gene Therapy Pharmaceuticals. Its primary akta.pro industry code is HLAAACAE, Gene Therapy for Rare/Monogenic Diseases, with a secondary code of HLAAACAG, Ophthalmology Gene Therapies. Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireBatten Disease Pipeline Market Research 2025: Opportunities with Over 10 Companies Developing 12+ Drugs in Varied Clinical StagesResearchAndMarkets.com has released a market research report titled 'Batten Disease - Pipeline Insight, 2025', providing an analysis of over 10 companies developing more than 12 drugs for Batten disease across various clinical stages. The report highlights novel therapeutic approaches including gene therapy and enzyme replacement, with key pipeline drugs such as PLX-200 by Polaryx Therapeutics in Phase III and TTX-381 by Tern Therapeutics in Phase I/II, both receiving FDA Fast Track designation. The analysis covers inactive pipeline products, collaborations, and funding activities to assess the current and future drug development landscape for this rare inherited nervous system disorder.PR NewswireAndelyn Biosciences and Tern Therapeutics Partner for Late-Stage Process Performance Qualification (PPQ) Manufacturing of AAV Gene Therapy for the Treatment of CLN2 Batten DiseaseAndelyn Biosciences has partnered with Tern Therapeutics to perform late-stage Process Performance Qualification (PPQ) manufacturing of TTX-381, an investigational AAV gene therapy targeting vision loss in children with CLN2 Batten disease. TTX-381 is a one-time subretinal gene therapy designed to deliver a functional copy of the TPP1 gene to preserve patient vision in this ultra-rare pediatric neurodegenerative disorder, which has no currently available treatments for its ocular manifestations. The collaboration leverages Andelyn's expertise in AAV vector manufacturing and PPQ batch production to advance the therapy toward patients.SecSEC FORM DOptoVista Holdings, LLC filed a Form D with the SEC for an exempt securities offering under Regulation D Rule 506(c), with total proceeds of $13,978,813 USD. The filing lists several executive officers and directors from Tern Therapeutics as related persons to the issuer. This regulatory submission discloses the details of the private capital raise initiated in August 2024.Eyes On EyecareNewly-launched Tern Therapeutics acquires ex-REGENXBIO gene therapiesTern Therapeutics, founded by former REGENXBIO executives, launched with $15M in funding led by ATW Partners and Steve Oliveira. The company is developing two gene therapies for CLN2 disease: TTX-381 for ocular symptoms and TTX-181 for CNS symptoms, both with FDA designations. The funding will support ongoing clinical testing of TTX-381.American City Business JournalsRegenxBio alums launch Tern Therapeutics with $15MThree former RegenxBio executives launched Tern Therapeutics with $15M in funding and a licensing deal for two gene therapies for Batten disease. The company plans to resume a phase 1/2 trial in London for its lead candidate TTX-381, with no timeline disclosed.LinkedIn#genetherapy #cellandgenetherapy #biotech #cgtweeklyTern Therapeutics has launched with $15 million in funding to develop one-time gene therapies for rare diseases, specifically targeting CLN2 Batten disease. The company was founded by industry veterans previously associated with REGENXBIO and is supported by investors including ATW Partners.